NUCLEOLIN and thrombotic microangiopathy: In 2010, several others were in clinical trial: AS1411 from Antisoma against nucleolin (phase II, acute myeloid leukemia); REG1/RB006 from Regado Biosciences against nucleolin (phase II, percutaneous coronary intervention); or ARC1779 from Archemix against A1 domain of von Willebrand factor (phase II, thrombotic microangiopathies) (for more complete descriptions of aptamers in clinical trials, see [92]).